Table 2.
Baseline characteristics by NT-proBNP
| NT-proBNP | n | NT-proBNP | n | NT-proBNP | n | NT-proBNP | n | NT-proBNP | n | P values | |
| Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | |||||||
| (5–241 pg/mL) | (242–628 pg/mL) | (629–1499 pg/mL) | (1500–3263 pg/mL) | (>3263 pg/mL) | |||||||
| Clinical characteristics | |||||||||||
| Age, years (IQR) | 56 (48–66) | 329 | 65 (57–73) | 353 | 69 (61–75) | 364 | 71 (66–77) | 365 | 73 (67–81) | 368 | <0.001 |
| Female gender, n (%) | 74 (22) | 329 | 136 (39) | 353 | 152 (42) | 365 | 188 (52) | 365 | 178 (48) | 368 | <0.001 |
| CHA2DS2-VASc (IQR) | 1 (0–2) | 275 | 2 (1–4) | 330 | 3 (2–4) | 346 | 3 (2–4) | 357 | 3 (2–4) | 360 | <0.001 |
| Laboratory | |||||||||||
| hs-TnT, ng/L (IQR) | 8.0 (5.0–14.0) | 329 | 10.0 (6.0–17.0) | 353 | 13.0 (8.0–25.0) | 365 | 16.0 (10.0–29.0) | 365 | 30.0 (19.0–57.0) | 368 | <0.001 |
| Creatinine, mg/dL (IQR) | 0.9 (0.8–1.1) | 326 | 1.0 (0.8–1.1) | 353 | 1.0 (0.9–1.2) | 363 | 1.0 (0.8–1.2) | 364 | 1.2 (1.0–1.6) | 366 | <0.001 |
| Comorbidities | |||||||||||
| Heart failure, n (%) | 60 (18.2) | 329 | 61 (17.3) | 353 | 83 (22.7) | 365 | 80 (21.9) | 365 | 116 (31.5) | 368 | <0.001 |
| Hypertension, n (%) | 155 (47.1) | 329 | 233 (66.0) | 353 | 258 (70.7) | 365 | 254 (69.6) | 365 | 251 (68.2) | 368 | <0.001 |
| DM, n (%) | 30 (9.1) | 329 | 61 (17.3) | 353 | 64 (17.5) | 365 | 52 (14.3) | 365 | 75 (20.4) | 368 | 0.001 |
| TIA, n (%) | 6 (2.0) | 329 | 3 (0.9) | 353 | 10 (2.7) | 365 | 7 (1.9) | 365 | 9 (2.5) | 368 | 0.421 |
| Stroke, n (%) | 7 (2.1) | 329 | 12 (3.4) | 353 | 21 (5.8) | 365 | 25 (6.9) | 365 | 27 (7.3) | 368 | 0.006 |
| CAD, n (%) | 20 (6.1) | 329 | 44 (12.5) | 353 | 65 (17.8) | 365 | 82 (22.5) | 365 | 115 (31.3) | 368 | <0.001 |
| Previous MCI, n (%) | 10 (3.0) | 329 | 24 (6.8) | 353 | 30 (8.2) | 365 | 44 (12.1) | 365 | 55 (15.0) | 368 | <0.001 |
| PAD, n (%) | 8 (2.4) | 329 | 9 (2.6) | 353 | 15 (4.1) | 365 | 25 (6.9) | 365 | 25 (6.8) | 368 | 0.004 |
| Hyperlipidaemia, n (%) | 96 (29.2) | 329 | 104 (29.5) | 353 | 136 (37.3) | 365 | 126 (34.5) | 365 | 103 (28.0) | 368 | 0.031 |
| Current smoker, n (%) | 20 (6.1) | 329 | 16 (4.5) | 353 | 16 (4.5) | 365 | 21 (5.8) | 365 | 20 (5.4) | 368 | 0.17 |
| COPD, n (%) | 15 (4.6) | 329 | 24 (6.8) | 353 | 27 (7.4) | 365 | 33 (9.0) | 365 | 57 (15.5) | 368 | <0.001 |
| Medication | |||||||||||
| Beta-blockers, n (%) | 90 (27.4) | 329 | 146 (41.4) | 353 | 159 (43.6) | 365 | 182 (49.9) | 365 | 206 (56.0) | 368 | <0.001 |
| Amiodaron, n (%) | 41 (12.5) | 329 | 73 (20.7) | 353 | 69 (18.9) | 365 | 77 (21.1) | 365 | 79 (21.5) | 368 | 0.016 |
| VKA, n (%) | 57 (17.3) | 329 | 102 (28.9) | 353 | 133 (36.4) | 365 | 113 (31.0) | 365 | 112 (30.4) | 368 | <0.001 |
| NOAC, n (%) | 37 (11.3) | 329 | 47 (13.3) | 353 | 54 (14.8) | 365 | 58 (15.9) | 365 | 42 (11.4) | 368 | 0.273 |
| Diuretics, n (%) | 26 (7.9) | 329 | 54 (15.3) | 353 | 89 (24.4) | 365 | 84 (23.0) | 365 | 136 (37.0) | 368 | <0.001 |
Baseline characteristics by all five quintiles of NT-proBNP.
CAD, coronary artery disease, COPD, chronic obstructive pulmonary disease, DM, diabetes mellitus, hs-TnT, high-sensitive troponin T, MCI, myocardial infarction, NOAC, new oral anticoagulant, NT-proBNP, N-terminal pro-brain natriuretic peptide, PAD, peripheral artery disease, VKA, vitamin K antagonist.